Invariant natural killer T (iNKT) cells recognize abnormal cells, but their T cell receptor is not variable and kill cancerous or infected target cells without MHC I restriction. Here, the authors show that in a clinical trial, donor-unrestricted allogeneic iNKT cells could be safely administered to human COVID-19 patients suffering from acute respiratory distress syndrome and trigger an anti-inflammatory response.
All Keywords
【저자키워드】 SARS-CoV-2, Phase I trials, Immunotherapy, NKT cells,
【저자키워드】 SARS-CoV-2, Phase I trials, Immunotherapy, NKT cells,